Abstract
Before discussing the significance of PGI2 in thrombosis, it is appropriate to acknowledge that its discovery is due to the contributions of three groups. First, credit should be given to Pace-Asciak and Wolfe (1) who in 1971 were working together at McGill University in Montreal. They isolated, identified, and described the unique chemical properties of a noval compound, 6(9)-oxyprostaglandin F2α, which was produced from arachidonic acid by homogenates of rat stomach. Secondly, we would not even be discussing PGI2 today were it not for the discoveries of Moncada, Gryglewski, Vane and others (2,3,4) at the Wellcome Research Laboratories in England. They showed that blood vessels make a prostaglandin, temporarily named PGX, with unique and potent biological properties. Finally, credit is due to Johnson, Morton, and others of The Upjohn Company (5) who collaborated with the Wellcome group and proved that the names 6(9)-oxyprostaglandin F2α and PGX are synonymous. They suggested the use of the trivial name prostacyclin to describe PGX, and I suspect that PGI2 will continue to be called prostacyclin henceforth.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Pace-Asciak C, Wolfe LS: A novel prostaglandin derivative formed from arachidonic acid by rat stomach homogenates. BIOCHEMISTRY 10: 3657–3664, 1971.
Moncada S, Gryglewski R, Bunting S, Vane JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. NATURE 263: 663–665, 1976.
Gryglewski RJ, Bunting S, Moncada S, Flower RJ, Vane JR: Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. PROSTAGLANDINS 12: 685–713, 1976.
Moncada S, Gryglewski RJ, Bunting S, Vane JR: A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. PROSTAGLANDINS 12: 715–737, 1976.
Johnson RA, Morton DR, Kinner JH, Gorman RR, McGuire JC, Sun FF, Whittaker N, Bunting S, Salmon J, Moncada S, Vane JR: The chemical structure of prostaglandin X (prostacyclin). PROSTAGLANDINS 12: 915–928, 1976.
Hamberg M, Samuelsson B: Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. PROC NATL ACAD SCI USA 70: 899–903, 1973.
Nugteren DH, Hazelhof E: Isolation and properties of intermediates in prostaglandin biosynthesis. BIOCHIM BIOPHYS ACTA 326: 448–461, 1973.
Hamberg M, Svensson J, Wakabayashi T, Samuelsson B: Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. PROC NATL ACAD SCI USA 71: 345–349, 1974.
Pace-Asciak C: A new prostaglandin metabolite of arachidonic acid. Formation of 6-keto-PGFlu by the rat stomach. EXPERENTIA 32: 291–292, 1976.
Hamberg M, Samuelsson B: Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. PROC NATL ACAD SCI USA 71: 3400–3404, 1974.
Hamberg M, Svensson J, Samuelsson B: Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. PROC NATL ACAD SCI USA 72: 2994–2998, 1975.
Gorman RR, Bunting S, Miller OV: Modulation of human platelet adenylate cyclase by prostacyclin (PGX). PROSTAGLANDINS 13: 377–388, 1977.
Tateson JE, Moncada S, Vane JR: Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. PROSTAGLANDINS 13: 389–397, 1977.
Saba SR, Mason RG: Studies of an activity from endothelial cells that inhibits platelet aggregation, serotonin release, and clot retraction. THROMB RES 5: 747–757, 1974.
Weksler BB, Marcus AJ, Jaffe EA: Synthesis of PGI2 (prostacyclin) by cultured human and bovine endothelial cells. PROC NATL ACAD SCI USA (In Press).
Harker LA, Joy N, Wall RT, Quadracci L, Striker G: Inhibition of platelet reactivity by endothelial cells (Abstract). THROMB HAEMOSTAS 38: 137, 1977.
Wen-Chang C, Murota S: Identification of 6-ketoprostaglandin Fla formed from arachidonic acid in bovine seminal vesicles. BIOCHIM BIOPHYS ACTA 486: 136–144, 1977.
Weiss HJ, Aledort LM, Kochwa S: The effect of salicylates on the hemostatic properties of platelets in man. J CLIN INVEST 47: 2169–2180, 1968.
Silver MJ, Hoch W, Kocsis JJ, Ingleman CM, Smith JB: Arachidonic acid causes sudden death in rabbits. SCIENCE 183: 1085–1087, 1974.
Uzunova A, Ramey E, Ramwell PW: Effect of testosterone, sex and age on experimentally induced arterial thrombosis. NATURE 261: 712–713, 1976.
Uzunova AD, Ramey ER, Ramwell PW: Arachidonate-induced thrombosis in mice: Effect of gender or testosterone and estradiol administration. PROSTAGLANDINS 13: 995–1002, 1977.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1978 Springer Science+Business Media New York
About this chapter
Cite this chapter
Smith, J.B. (1978). A Discussion of the Possible Significance of PGI2 in Thrombosis. In: Day, H.J., Molony, B.A., Nishizawa, E.E., Rynbrandt, R.H. (eds) Thrombosis. Advances in Experimental Medicine and Biology, vol 102. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-1217-9_19
Download citation
DOI: https://doi.org/10.1007/978-1-4757-1217-9_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-1219-3
Online ISBN: 978-1-4757-1217-9
eBook Packages: Springer Book Archive